Maruti Suzuki India posts 6% YoY decline in total sales for June 2025; Export performance at all-time monthly high
Maruti Suzuki India reported a 6% drop in total sales for June 2025, selling 167,993 units compared to 179,228 units in the same month last year. The decline was largely driven by weaker domestic demand, although the company recorded its highest-ever monthly exports.
In the domestic market, Maruti sold 121,339 vehicles in June, including 2,433 units of its light commercial vehicle, Super Carry. Passenger vehicle sales stood at 118,906 units, down from 137,160 units in June 2024.
Sales of mini and compact cars — which include popular models like the Alto, WagonR, and Baleno — fell sharply, dropping to 60,591 units from 73,444 a year earlier. The mid-size sedan Ciaz also saw muted numbers, with just over 1,000 units sold.
Utility vehicles, a category that includes models like the Brezza, Ertiga, and Grand Vitara, contributed 47,947 units to the monthly tally, slightly lower than last year. Meanwhile, van sales, primarily led by the Eeco, also slipped year-on-year.
On a more positive note, Maruti's exports touched 37,842 units in June — the highest monthly number ever for the company. Sales to other original equipment manufacturers (OEMs) came in at 8,812 units.
Looking at the broader April-June quarter, Maruti's total sales stood at 527,861 units, marginally up from 521,868 units in the same period last year.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
V2 Retail Q1 FY26 business update: Company reports 51% YoY revenue growth, adds 28 new stores
V2 Retail Limited has reported a strong start to FY26, delivering impressive growth in its Q1 business update. The company's standalone revenue surged to ₹628 crore in Q1 FY26, marking a 51% year-on-year jump from ₹415 crore in Q1 FY25. This performance highlights the success of its product-first approach, robust sell-through rates, and deeper market reach. Same-store sales growth (SSSG) normalized at 10%, despite an early Eid impact in April. May and June recorded strong double-digit growth, reflecting steady consumer demand and smart assortment planning. Sales per square foot for Q1 stood at ₹957, showing solid store-level productivity—even with a higher contribution from new stores. This was made possible through improved merchandising, faster stock replenishments, and strict inventory control. V2 Retail also expanded its footprint by opening 28 new stores during the quarter while closing one underperforming outlet. The total store count now stands at 216, covering a retail area of 23.48 lakh sq. ft. The company continues to focus on Tier 2 and Tier 3 cities, strengthening its mission to bring affordable fashion to emerging India. The company emphasized its strong momentum going into FY26, driven by innovation, data-backed merchandising, and customer trust. With an expanding footprint and a clear focus on value fashion, V2 Retail is well-positioned to lead in India's fast-evolving retail landscape. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 hours ago
- Business Upturn
Aurobindo Pharma's subsidiary CuraTeQ Biologics secures marketing approval for trastuzumab biosimilar ‘Dazublys'
Aurobindo Pharma's wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has achieved a major milestone with the European Commission granting marketing authorization for Dazublys™, its trastuzumab biosimilar. This approval follows the positive opinion issued by the European Medicines Agency's (EMA) CHMP in April 2025, recommending the product for authorization. Dazublys™ is a biosimilar of trastuzumab, a widely used monoclonal antibody in the treatment of HER2-positive breast and gastric cancers. With this latest approval, Dazublys™ becomes CuraTeQ's third EMA-approved biosimilar, following Dyrupeg™ (approved in April 2025) and Zefylti™ (approved in February 2025). It also marks the fourth biosimilar approval for CuraTeQ in the European region, including Bevqolva™, which received a green light from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in December 2024. This continued string of regulatory successes further strengthens Aurobindo Pharma's global biosimilar portfolio and underscores the company's commitment to expanding access to high-quality, affordable biologics in key regulated markets. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
5 hours ago
- Business Upturn
Stocks hitting 52-week highs today, July 2: Divi's Laboratories, Bharti Airtel, UltraTech Cement, Dalmia Bharat and more
By Aman Shukla Published on July 2, 2025, 15:45 IST Despite broader market weakness on July 2, several stocks managed to hit their 52-week highs, signalling strong investor interest. The Sensex slipped 287.60 points to close at 83,409.69, while the Nifty ended 88.40 points lower at 25,453.40. However, the following stocks stood out by touching fresh 52-week highs during the session. Key Stocks That Hit 52-Week Highs Today (July 2) Company Market Price (₹) 52-Week High (₹) Divi's Laboratories 6,859.50 (+0.04%) 6,885.50 Bharti Airtel 2,033.30 (+0.69%) 2,045.80 Laurus Labs 756.75 (+1.43%) 761.75 UltraTech Cement 12,436.00 (+1.85%) 12,527.00 SRF 3,255.60 (+1.74%) 3,281.60 JK Lakshmi Cement 986.00 (+3.56%) 995.00 Federal Bank 217.75 (-0.44%) 220.00 LT Foods 494.75 (+3.95%) 500.00 Dalmia Bharat 2,220.10 (+1.43%) 2,245.00 Ramco Cements 1,088.40 (+1.04%) 1,101.90 Asahi India Glass 830.55 (+3.01%) 842.00 L&T Finance 206.22 (-0.78%) 209.60 AU Small Finance Bank 818.25 (-2.40%) 841.00 KRBL 379.50 (+1.12%) 390.40 Gabriel India 976.20 (+15.84%) 1,011.30 Cholamandalam Financial Holdings 2,148.80 (+1.74%) 2,231.60 South Indian Bank 31.04 (-1.77%) 32.25 Fiem Industries 1,923.30 (-0.77%) 1,999.00 City Union Bank 221.44 (-3.93%) 232.55 Sai Life Sciences 789.10 (+1.19%) 838.50 Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Bharti AirtelDalmia BharatDivi's LaboratoriesStock MarketUltraTech Cement Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
